RNS Number: 9734 S GlaxoSmithKline PLC 14 July 2020 GlaxoSmithKline plc. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

RNS Number: 8743 S GlaxoSmithKline PLC 13 July 2020 GlaxoSmithKline plc. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

RNS Number: 7231 S GlaxoSmithKline PLC 10 July 2020 GlaxoSmithKline plc. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

RNS Number: 7180 S GlaxoSmithKline PLC 10 July 2020 GlaxoSmithKline plc. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

RNS Number: 7173 S GlaxoSmithKline PLC 10 July 2020 GlaxoSmithKline plc. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that data presented from the HIV Prevention Trials Network 083 study demonstrated the superior efficacy of investigational, long-acting, injectable cabotegravir administered every two months when compared to...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that data presented from the HIV Prevention Trials Network 083 study demonstrated the superior efficacy of investigational, long-acting, injectable cabotegravir administered every two months when compared to...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration has approved Rukobia, 600 mg extended-release tablets. Rukobia is a novel attachment inhibitor for the treatment of HIV-1 infection indicated for use in combination with...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration has approved Rukobia, 600 mg extended-release tablets. Rukobia is a novel attachment inhibitor for the treatment of HIV-1 infection indicated for use in combination with...

RNS Number: 7366 R GlaxoSmithKline PLC 01 July 2020. The Company's issued share capital as at 30 June 2020 consisted of 5,384,977,518 shares of 25 pence each, of which 367,705,950 Ordinary Shares were held in Treasury.. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

GSK receives first regulatory approval for Duvroq in Japan for patients with anaemia due to chronic kidney disease. Hal Barron, Chief Scientific Officer and President R&D, GSK, said: "The approval of Duvroq brings a new, convenient oral treatment option to nearly 3.5 million patients in Japan who have anaemia associated with renal disease.

RNS Number: 5484 Q GlaxoSmithKline PLC 19 June 2020 Issued: 19 June 2020, London UK- LSE announcement. GSK announces FDA Advisory Committee meeting to review belantamab mafodotin for the treatment of patients with relapsed/refractory multiple myeloma. GlaxoSmithKline plc today announced the US Food and Drug Administration will convene a meeting of the...

RNS Number: 4041 Q GlaxoSmithKline PLC 18 June 2020 GlaxoSmithKline plc. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

RNS Number: 1349 Q GlaxoSmithKline PLC 16 June 2020 GlaxoSmithKline plc. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration has approved Tivicay PD tablets for oral suspension, which are used in combination with other antiretroviral agents for the treatment of human immunodeficiency virus...

ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration has approved Tivicay PD tablets for oral suspension, which are used in combination with other antiretroviral agents for the treatment of human immunodeficiency virus...

RNS Number: 7206 P GlaxoSmithKline PLC 11 June 2020 GlaxoSmithKline plc. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

RNS Number: 4357 P GlaxoSmithKline PLC 09 June 2020 GlaxoSmithKline plc. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

RNS Number: 5569 O GlaxoSmithKline PLC 01 June 2020. The Company's issued share capital as at 31 May 2020 consisted of 5,384,879,604 shares of 25 pence each, of which 367,705,950 Ordinary Shares were held in Treasury.. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.